Hiroshi Uda

1PUBLICATIONS
0CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|Sep 13, 2018
Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.

Osamu Saiki, Hiroshi Uda

Pageof 1

Frequent Collaborators